Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:26 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,009 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
white button mushroom extract, flow cytometry, immunologic technique, laboratory biomarker analysis, gas chromatography-mass spectrometry, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Blood Collection During Standard of Care Treatment
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Conditions
Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
Other · Dietary Supplement · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Duarte, California
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
Interventions
Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total Marrow Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Ibrutinib, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
Yazeed Sawalha
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Richmond, Virginia
Conditions
Head and Neck Cancer
Interventions
DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry
Genetic
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
659
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Obesity
Interventions
Muscle Biopsy, Adipose Biopsy, Glucose Clamp, Accelerometer, Endurance Exercise, Physical activity/ dietary habits, Heavy Water Labeling Period
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Conditions
Solid Cancer
Interventions
BAY73-4506 (Regorafenib, Stivarga)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Conditions
CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Palbociclib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1065
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
Conditions
Childhood Infratentorial Ependymoma, Childhood Supratentorial Ependymoma, Newly Diagnosed Childhood Ependymoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Monrovia, California
Conditions
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
Conditions
Uterine Cervical Neoplasms
Interventions
MR Spectroscopy, Fat-Saturation and Diffusion-Weighted Imaging, Dynamic Contrast Enhancement MRI (MR-DCE), Diffusion Tensor Imaging (DTI)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cervical Degenerative Disc Disease
Interventions
PureGen Osteoprogenitor Cell Allograft
Biological
Lead sponsor
Alphatec Spine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Carlsbad, California • Middletown, Connecticut • Greensboro, North Carolina + 1 more
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Conditions
Small Cell Lung Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions
Magnetic Resonance Imaging, Prophylactic Cranial Irradiation
Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
428
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Completed No phase listed Observational Accepts healthy volunteers

The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer

NCT03304132
Conditions
Oral Cancer
Interventions
Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach, Classification of Oral Microbiome Using taxonomic approach
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 92 Years
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Ruxolitinib Phosphate
Other · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Rochester, Minnesota • Omaha, Nebraska
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami Lakes, Florida